Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fengshi Gutong Capsule is a traditional Chinese medicine (TCM) herbal formula approved by the China Food and Drug Administration for the treatment of osteoarthritis and other rheumatic conditions. It is composed of seven herbs, including Aconiti Radix Cocta, with major active components such as ursolic acid, kaempferol, ephedrine, hydroxysafflor yellow A, and glycyrrhizic acid. The mechanism of action involves inhibition of inflammatory pathways—specifically restraining activation of mitogen-activated protein kinases (MAPK), nuclear factor kappa B (NF-κB), activator protein-1 (AP-1), and Akt—which leads to reduced production of inflammatory mediators in synovial cells. Pharmacological studies suggest multi-component and multi-target effects that improve immune-inflammatory responses in osteoarthritis[1][3][4][7]. The product is widely used in China for arthritis-related pain relief.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Fengshi Gutong Capsule.